

Proposed Patient Information Leaflet

SCHEDULING STATUS

S4

ACRIPTEGA (film-coated tablets)

Lamivudine/ Tenofovir disoproxil fumarate/

Dolutegravir sodium

Contains sugar: Lactose monohydrate 136 mg

ACRIPTEGA contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 'sodium-free'.

ACRIPTEGA may lead to serious problems with your liver or cause too much acid in your blood. If left untreated, this may even cause death. The safety and efficacy of **ACRIPTEGA** in patients who are infected with both human immunodeficiency virus (HIV) and hepatitis B virus (HBV) have not been established. **ACRIPTEGA** should not be used for the treatment of chronic HBV infection. You should be closely monitored by your doctor for several months if you are infected with HBV and discontinue the use of **ACRIPTEGA**.

Read all of this leaflet carefully before you start taking **ACRIPTEGA**

- Keep this leaflet. You may need to read it again.
- If you have further questions, please ask your doctor, pharmacist, nurse or other health care provider.
- **ACRIPTEGA** has been prescribed for you personally and you should not share your medicine with other people. It may harm them, even if their symptoms are the same as yours.

What is in this leaflet

1. What **ACRIPTEGA** is and what it is used for.
2. What you need to know before you take **ACRIPTEGA**.

Approved: 27 November 2023

3. How to take **ACRIPTEGA**.
4. Possible side effects.
5. How to store **ACRIPTEGA**.
6. Contents of the pack and other information.

1. What ACRIPTEGA is and what it is used for

Each film-coated tablet contains the active substances:

Lamivudine

Tenofovir disoproxil fumarate

Dolutegravir sodium equivalent to dolutegravir

ACRIPTEGA belongs to a group of medicines, known as antiretrovirals.

Combination antiretroviral medicines, such as **ACRIPTEGA**, are used in the treatment of HIV-1 (human immunodeficiency virus-1) infection in adults aged 18 years and older.

ACRIPTEGA does not cure or prevent HIV infection; however, it helps to keep HIV from reproducing and appears to slow down the destruction of the immune system.

ACRIPTEGA will not keep you from spreading HIV to other people. Appropriate precautions must continue to be used.

2. What you need to know before you take ACRIPTEGA

Do not take ACRIPTEGA:

- If you are hypersensitive (allergic) to tenofovir disoproxil fumarate, lamivudine, dolutegravir or any of the other ingredients in **ACRIPTEGA** tablets.
- If you have or had kidney problems
- If you are a woman of child-bearing age and not using effective contraceptives.
- If you are pregnant or planning to become pregnant or breastfeeding.
- If you are taking any other tenofovir-containing or other lamivudine-containing, or emtricitabine-containing, or dolutegravir containing medicines
- If you are taking a medicine called adefovir dipivoxil (used for the treatment of chronic hepatitis B)

Approved: 27 November 2023

- If you are taking a medicine called dofetilide and pilsicainide (used for the treatment of abnormal heartbeat – cardiac dysrhythmias)
- If you are taking a medicine called didanosine (used for the treatment of HIV infection).
- If you are younger than 18 years of age.
- If you have moderate to severe liver failure

Warnings and precautions:

Safety and efficacy of the individual active ingredients in various antiretroviral combination regimens with similar dosages as contained in **ACRIPTEGA** have been established in clinical studies for the treatment of HIV patients. However, safety and efficacy of the fixed drug combination as in **ACRIPTEGA** for the treatment of HIV have not been established in clinical studies.

ACRIPTEGA will not keep you from spreading HIV to other people. Appropriate precautions must continue to be used.

- If you are a female, overweight or have been taking nucleoside-containing medicines for a long time, as you are more likely to get lactic acidosis (build-up of lactic acid in the body) (see information about lactic acidosis under **4. Possible side effects**).
- **High cholesterol:** If you have been told you have high cholesterol (certain bad fats that are too high in the blood), you could be at risk of getting heart disease or having a heart attack.
- **Increase blood sugar levels:** **ACRIPTEGA** may contribute to your sugar levels increasing, this may also cause insulin resistance where the insulin levels in your pancreas have a poor response to insulin.
- **Increased blood lactate levels:** high blood lactate levels in combination with lactic acidosis may be caused by an imbalance of oxygen that is being delivered to the tissues in your body.
- **Kidney problems.** Before starting treatment, your doctor may order blood tests to assess your kidney function and may advise you to take **ACRIPTEGA** tablets less often. Do not reduce the prescribed dose unless your doctor has told you to do so. Your doctor may also order blood tests during treatment to monitor how your kidneys work.

Approved: 27 November 2023

- **Bone problems.** Some people taking combination medicines for HIV develop a condition called osteonecrosis (death of bone tissue caused by loss of blood supply to the bone). You must contact your doctor if you experience joint aches and pain, joint stiffness or difficulty in movement.
- **Liver problems.** If you have liver problems including Hepatitis B virus infection.
- **Hepatitis B or C.** If you have Hepatitis B or C, you are at increased risk for severe and potentially fatal liver adverse reactions.
- **Opportunistic infections.** Signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment such as **ACRIPTEGA** is started. It is believed that these symptoms are due to an improvement in the body's immune response, enabling the body to fight infections that may have been present with no obvious symptoms. If you notice any symptoms of infection, please inform your doctor immediately.
- **Pancreas disorders.** If you develop abdominal pain, nausea, vomiting, contact your doctor as it could indicate problems with your pancreas.
- **Changes in body fat.** Changes in body fat develop in some patients taking **ACRIPTEGA**. These changes may include an increased amount of fat in the upper back and neck ("buffalo hump"), in the breasts and around the trunk. Loss of fat from the legs, arms and face may also happen. The cause and long-term health effects of these fat changes are not known.
- **DEPRESSION** (including suicidal ideation).
Patients should inform their doctor if they notice any symptoms of depression during treatment.
- **ACRIPTEGA** helps to control (treat) HIV infection but is not a cure. You will need to take it every day. You must not stop taking **ACRIPTEGA** without first talking to your doctor. If you are concerned that you may be developing symptoms of a hypersensitivity reaction, call your doctor immediately who will advise whether you must stop taking **ACRIPTEGA**. You may continue to develop other infections and other illnesses associated with HIV disease. You should therefore keep in regular contact with your doctor while you are taking **ACRIPTEGA**.

Approved: 27 November 2023

- Treatment with **ACRIPTEGA** has not been shown to reduce the risk of passing HIV infection to others through sexual contact or contaminated blood. If you are sexually active you should continue to use appropriate precautions to prevent this.
- To protect other people from becoming infected with HIV:
 - **a condom must be used** when you have oral or penetrative sex;
 - **blood transfer should be avoided** – for example, needles must not be shared.

Children and adolescents:

Do not give this medicine to children under the age of 18 years

Other medicines and ACRIPTEGA:

Always tell your health care provider if you are taking any other medicine. (This includes all complementary or traditional medicines.)

Do not take ACRIPTEGA if you are already taking any of the following medicines:

- Other medicines that contain tenofovir disoproxil fumarate, lamivudine, dolutegravir or emtricitabine, either alone, or in other formulations.

ACRIPTEGA should not be used with these medicines because they contain the same or similar active ingredients as ACRIPTEGA.

- Medicines that contain didanosine. Tenofovir disoproxil fumarate (an ingredient in **ACRIPTEGA**) may cause the amount of didanosine in your blood to increase. You may need to be followed more carefully if you are taking **ACRIPTEGA** and didanosine together. The dose of didanosine may need to be reduced.
- Adefovir dipivoxil (used for the treatment of chronic hepatitis B).
- Zalcitabine (antiretroviral treatment).
- Trimethoprim, as in co-trimoxazole (an antibiotic), may cause an increase in **ACRIPTEGA** plasma levels. If you have no kidney disease, a dosage adjustment is not necessary.
- Rifampicin (antibiotic used to treat several types of bacteria) may decrease the blood levels of dolutegravir.
- Isoniazid (antibiotic used to treat tuberculosis) increased the concentration.
- Polyvalent cation-containing antacids. Recommended to be administered 2 hours before or 6 hours after **ACRIPTEGA**.

Approved: 27 November 2023

- Calcium supplements: recommended to be administered 2 hours before or 6 hours after **ACRIPTEGA** or taken with food.
- Iron supplements: recommended to be administered 2 hours before or 6 hours after **ACRIPTEGA** or taken with food.
- Metformin: co-administered with **ACRIPTEGA** may increase plasma levels of insulin.
- Oral contraceptives: **ACRIPTEGA** does not change the concentration levels of oral contraceptives.
- Methadone (a pain killer): **ACRIPTEGA** does not change the concentration levels of this painkiller.

Some patients who are taking **ACRIPTEGA** may continue to experience infections and the use of antibiotics may have to be considered.

ACRIPTEGA with food and drink:

ACRIPTEGA can be taken without regard to food.

Pregnancy and breastfeeding and fertility

Women of childbearing potential:

Women of childbearing potential should be counselled about the potential risk of birth defects of the brain and spine with dolutegravir, including consideration of using effective contraceptive measures.

Perform pregnancy testing before start of **ACRIPTEGA** in women of childbearing potential to exclude unintentional use of **ACRIPTEGA** during the first trimester of pregnancy.

If a woman plans pregnancy, the benefits and the risks of starting or continuing treatment with dolutegravir versus using another antiretroviral medicine should be discussed with her.

Pregnancy:

Do not take **ACRIPTEGA** tablets if you are pregnant or breast-feeding (see **2. What you need to know before you take ACRIPTEGA**). **ACRIPTEGA** could seriously harm your

Approved: 27 November 2023

unborn child if you fall pregnant while on treatment or if you start taking **ACRIPTEGA** in the first few weeks of your pregnancy.

If you are pregnant or breast-feeding your baby, think you may be pregnant or are planning to have a baby, please consult your doctor, pharmacist, or other health care provider for advice before taking **ACRIPTEGA**.

Use of dolutegravir during pregnancy was associated with a small increase in the birth defects of the brain and spine.

If a pregnancy is confirmed in the first trimester while on dolutegravir, the benefits and risks of continuing dolutegravir versus switching to another antiretroviral medicine should be discussed with the patient. Dolutegravir may be used during the second and third trimester of pregnancy when the expected benefit outweighs the potential risk to the foetus.

You should ensure that you always used effective contraception while you are taking **ACRIPTEGA**. Your healthcare professional can advise you on which contraceptives to take. Never stop taking **ACRIPTEGA** without first consulting your healthcare professional as your HIV condition may become worse.

If you are thinking about having a baby, do not stop using **ACRIPTEGA** and contraception before you have talked to your healthcare professional. If you think you are pregnant go to your healthcare professional to get a pregnancy test and to be advised on your future HIV treatment and on a pregnancy management plan.

Breast-feeding:

Do not breast-feed your baby if you are taking **ACRIPTEGA**.

HIV infected women should not breast-feed their infants in order to avoid transmission of HIV or follow appropriate guidelines.

Dolutegravir is excreted in human breast milk, and there is significant exposure to the neonate/infants due to slow removal. There is insufficient information on the effects of dolutegravir in neonates/infants.

Fertility:

There are no data on the effects of dolutegravir on human male or female fertility.

Approved: 27 November 2023

Driving and using machinery

ACRIPTEGA may affect the ability to drive and use machines. **ACRIPTEGA** can make you feel dizzy or sleepy and may have other side effects and make you less alert. Make sure you know how you react to **ACRIPTEGA** before you drive, use machines, or do anything else that could be dangerous.

ACRIPTEGA tablets contains lactose and sodium

ACRIPTEGA tablets contains lactose:

Patients with the rare hereditary conditions of lactose or galactose intolerance should not take **ACRIPTEGA**.

If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking **ACRIPTEGA**.

ACRIPTEGA tablets contains lactose monohydrate which may have an effect on the control of your blood sugar if you have diabetes mellitus.

ACRIPTEGA tablets contains sodium:

ACRIPTEGA contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 'sodium-free'.

3. How to take ACRIPTEGA

Do not share medicines prescribed for you with any other person.

Treatment should be prescribed and initiated by a doctor experienced in the management of HIV infection.

Always take **ACRIPTEGA** exactly as your doctor has instructed you. You should check with your doctor or pharmacist if you are unsure.

The usual dose of **ACRIPTEGA** is one tablet once a day.

ACRIPTEGA must be taken without regard of food.

You can only take **ACRIPTEGA** if you are older than 18 years.

Your doctor will tell you how long your treatment with **ACRIPTEGA** will last.

Approved: 27 November 2023

If you take more ACRIPTEGA than you should:

In the event of overdosage, consult your doctor or pharmacist. If neither is available, contact the nearest hospital or poison centre.

If you forget to take ACRIPTEGA:

If you forget to take a dose of **ACRIPTEGA**, take it as soon as you remember unless it is nearly time for your next dose and then continue as before.

Do not take a double dose to make up for missed individual doses.

If you stop taking ACRIPTEGA:

Do not suddenly stop taking **ACRIPTEGA** without consulting with your doctor first. If you have stopped taking **ACRIPTEGA** for any reason, especially if you think you are having side effects, or for another illness, it is important that you contact your doctor before restarting.

You should not stop treatment unless your doctor instructs you to. When your **ACRIPTEGA** supply starts to run low, get more from your healthcare provider or pharmacy. This is very important because the amount of virus in your blood may increase if the medicine is stopped for even a short time. The virus may develop resistance to the ingredients in **ACRIPTEGA** and become harder to treat.

If you have the impression that the effect of **ACRIPTEGA** is too strong or too weak, talk to your doctor or pharmacist.

4. Possible side effects

ACRIPTEGA can have side effects.

Not all side effects reported for **ACRIPTEGA** are included in this leaflet. Should your general health worsen or if you experience any untoward effects while taking **ACRIPTEGA**, please consult your health care provider for advice.

If any of the following happens, stop taking ACRIPTEGA and tell your doctor immediately or go to the casualty department at your nearest hospital:

- Sudden swelling of hands, face, lips, mouth, tongue and throat or mucous membranes with difficulty breathing and/or itching and rash

Approved: 27 November 2023

These are all very serious side effects. If you have them, you may have had a serious allergic reaction to **ACRIPTEGA**.

• Serious liver problems (hepatitis) with liver enlargement (hepatomegaly) and fat in the liver (steatosis). The following are signs of the liver problems:

- Yellow discolouration of the skin and the white part of your eyeballs
- Darkening of your urine
- Your bowel movements turn lighter in colour
- You feel sick to your stomach (nausea)
- You have stomach pain

You may need urgent medical attention or hospitalisation.

LACTIC ACIDOSIS:

Some people who have taken medicines like ACRIPTEGA (nucleoside analogues) have developed a serious condition called lactic acidosis (build- up of acid in the blood). Lactic acidosis can be a medical emergency and may need to be treated in the hospital. Call your doctor immediately if you get the following signs or symptoms of lactic acidosis:

- You feel very weak or tired
- You have unusual (not normal) muscle pain
- You have trouble breathing
- You have stomach pain with nausea and vomiting
- You feel cold, especially in your arms and legs
- You feel dizzy or lightheaded
- You have a fast or irregular heartbeat

This side effect can cause inflammation of the pancreas, liver and kidney failure, and has occasionally been fatal. Lactic acidosis also occurs more often in women, particularly if they are overweight. If you have liver disease, you may also be more at risk of getting this condition. While you are being treated with **ACRIPTEGA**, your doctor will monitor you closely for any signs that you may be developing lactic acidosis.

Tell your doctor if you notice any of the following:

Approved: 27 November 2023

Frequent:

- Headache
- Difficulty in sleeping (insomnia)
- Nausea, vomiting
- Upper abdominal pain
- Diarrhoea, flatulence
- Rash, itching
- Hair loss
- Joint pain (arthralgia)
- Muscles become weak, painful and may even cause paralysis (Muscle disorder)
- Feeling tired, weak (fatigue)
- Feeling of bodily discomfort (malaise)
- Fever

Less Frequent:

- Depression Neutropenia (low white blood cell count)
- Anaemia (low red blood cell count)
- Increased bruising or bleeding (thrombocytopenia)
- Increases in enzymes produced by the liver
- Allergic reaction (hypersensitivity)
- Immune system begins to recover (immune reconstitution syndrome)
- Abdominal pain or discomfort
- Hepatitis (disease of the liver)
- Bone marrow stops making red blood cells (pure red cell aplasia)
- Redistribution/ accumulation of body fat)
- Abnormal sensation of tingling, numbness or burning (paraesthesia)
- Peripheral neuropathy (when the nerves carrying messages to and from the brain are damaged)
- Inflammation of the pancreas, which causes severe pain in the abdomen and back
- Abnormal muscle breakdown which can lead to kidney problems
- Decrease in bone mineral density
- Bones are more porous than they should be (osteopenia)
- Fractures

Approved: 27 November 2023

- Abnormally low levels of phosphate in the blood (hypophosphataemia)
- Shortness of breath (dyspnea)
- Chronic kidney disease, or kidney failure (renal insufficiency)
- Nose and throat infection
- Nasal discharge and congestion
- Increased blood sugar levels
- Feeling depressed
- Cough
- Loss of appetite

If you notice any side effects not mentioned in this leaflet, please inform the medical practitioner or pharmacist.

Reporting of side effects

If you get side effects, talk to your doctor, pharmacist or nurse.

You can also report side effects to SAHPRA on the SAHPRA website at:

<https://medsafety.sahpra.org.za/#download>, via email at: adr@sahpra.org.za or via telephone at: 0125010311

By reporting side effects, you can help provide more information on the safety of ACRIPTEGA.

5. How to store ACRIPTEGA

- STORE ALL MEDICINES OUT OF REACH OF CHILDREN.
- Store at or below 30 °C. Store in the original container. Do not remove from the carton until required for use. Bottles must be kept tightly closed.
- Do not store in a bathroom.
- Do not use after the expiry date stated on the label.
- Return all unused medicine to your pharmacist.
- Do not dispose of unused medicine in drains or sewerage systems (e.g. toilets).

6. Contents of the pack and other information

What ACRIPTEGA contains

Approved: 27 November 2023

- The active substances are

Lamivudine,

Tenofovir disoproxil fumarate,

Dolutegravir sodium

Each **ACRIPTEGA** film-coated tablet contains 300 mg lamivudine, 300 mg tenofovir disoproxil fumarate, and dolutegravir sodium equivalent to dolutegravir 50 mg.

- The other ingredients are: croscarmellose sodium, magnesium stearate, microcrystalline cellulose; povidone; sodium starch glycolate {film-coating colourant: Opadry II white: macrogol / PEG 4000; polyvinyl alcohol – part. hydrolysed; talc; titanium dioxide: Aqua-Il White (A22D10542): polyvinyl alcohol; polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc}

What ACRIPTEGA looks like and contents of the pack:

ACRIPTEGA is packed in a round, blue, opaque High-Density Polyethylene (HDPE) bottle, round wide mouth, blue with blue opaque polypropylene (PP) screw closure and with wad containing aluminium induction sealing liner. Packed in an outer carton.

Pack sizes of 28's, 30's, 84's, 90's and 180's.*

* Not all packs and pack sizes may be marketed.

What ACRIPTEGA looks like:

White to off white, film-coated, capsule-shaped, biconvex bevelled edge tablet debossed with "M" on one side and "LTD" on the other side of the tablet.

Holder of Certificate of Registration and Manufacturer

Viartis Healthcare (Pty) Ltd

4 Brewery Street,

Isando,

Kempton Park, 1600

Republic of South Africa

This leaflet was last revised in

Date of publication: 31 August 2021

Viartis Healthcare (Pty) Ltd

Acriptega

Each tablet contains 300 mg tenofovir disoproxil fumarate/ 300 mg lamivudine/ 50 mg dolutegravir

Approved: 27 November 2023

Date of revision of text: 05 September 2022

Date of revision of text: 27 November 2023

Registration number

52/20.2.8/0199 (Acriptega – master)

Access to the corresponding Professional Information

Can be obtained on the SAHPRA website